利润“失血”28％！博雅生物剥离副业忙自救，能否熬过血液制品转型关？

Core Viewpoint - The financial performance of China Resources Boya Biological Pharmaceutical Group Co., Ltd. (Boya Bio) reflects a challenging transition period, with revenue growth not translating into profit, highlighting the dual challenges of industry-wide centralized procurement and technological pressures [1][3][10] Financial Performance - In the first half of 2025, Boya Bio reported revenue of 1.008 billion yuan, a year-on-year increase of 12.51%, while net profit attributable to shareholders fell to 225 million yuan, a decline of 28.68% [1][2] - The gross profit margin decreased significantly by 14.02 percentage points to 53.01% compared to the same period last year [1][2] Industry Context - The "increase in revenue but decrease in profit" phenomenon is not unique to Boya Bio but is a common issue across the blood products industry, with major players experiencing net profit declines exceeding 20% in the first quarter of 2025 [3][4] - The price decline of blood products, influenced by regional centralized procurement initiatives, has put direct pressure on profit margins, with prices for certain products like immunoglobulin dropping by approximately 12.59% [3][4] Strategic Focus - Boya Bio is focusing on its core blood products business while divesting non-core assets, having sold stakes in several companies since 2023, with the latest sale in July 2025 resulting in a 25.8% discount from the initial listing price [5][6] - The company aims to stabilize operations at its remaining subsidiary, Xinbai Pharmaceutical, and enhance asset and product efficiency [1][5] Growth Initiatives - Boya Bio has expanded its plasma collection network, increasing the number of plasma stations to 21 across seven provinces, which is expected to enhance raw plasma supply [2][6] - The company is investing in research and development, with R&D expenditures reaching 44.72 million yuan in the first half of 2025, accounting for 4.44% of revenue [9] Challenges and Opportunities - The blood products industry is undergoing significant transformation, with tight plasma resources and increasing competition from imported products, which now account for 69% of the domestic market for albumin [8][10] - Boya Bio is actively pursuing technological innovations and collaborations to enhance its product offerings and operational efficiency, including the establishment of smart factories expected to improve production automation [9][10]